Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection

OBJECTIVES: Baloxavir marboxil (formerly S-033188) is a first-in-class, orally available, cap-dependent endonuclease inhibitor licensed in Japan and the USA for the treatment of influenza virus infection. We evaluated the efficacy of delayed oral treatment with baloxavir marboxil in combination with...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:J Antimicrob Chemother
Κύριοι συγγραφείς: Fukao, Keita, Noshi, Takeshi, Yamamoto, Atsuko, Kitano, Mitsutaka, Ando, Yoshinori, Noda, Takahiro, Baba, Kaoru, Matsumoto, Kazumi, Higuchi, Naoko, Ikeda, Minoru, Shishido, Takao, Naito, Akira
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Oxford University Press 2019
Θέματα:
Original Research
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6376846/
https://ncbi.nlm.nih.gov/pubmed/30476172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dky462
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια